Generic drug retail sales grow 30% during first half of 1995; hospital market is sluggish.
Executive Summary
GENERIC DRUG RETAIL SALES GROWTH OF 30% IN FIRST HALF OF 1995 compares with 50% in 1994, according to data presented by IMS International Senior VP Stephen Chappell at a Nov. 9-10 pharmaceutical conference sponsored by the Massachusetts Institute of Technology in Cambridge, Mass. The decrease is "not surprising" and "should not be viewed as an enormous slow-down in the generic market," Chappell remarked. He noted that the 1994 figures for the generics industry reflect the impact of a series of branded products going off patent in 1993 and 1994. In 1993, generic sales increased by 25%, Chappell noted.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth